Advancements in Cell & Gene Therapy: New Therapeutic Horizons

Basel Biozentrum, 15th September 2023

Spanning multiple therapeutic areas from regenerative medicine to immunotherapy, the simplistic approach of repurposing patients' autologous cells has been a ground-breaking therapeutic approach greatly expanding the horizon of potential medicines. Join us on the 15th of September 2023, to learn the newest advancements in cell & gene therapy and network with pioneering scientist from academia, pharma and biotech in Switzerland.

10:00-10:30	**Registration and coffee**
10:30-10:40	*Event welcome & ELRIG introduction*
1st session: Advancements in cell therapy *Session Chair: Ben Taylor, Ph.D., AstraZeneca*	
10:40-11:10	Molecular cell shielding – A therapeutic platform approach for hematologic diseases *Prof. Dr. Lukas Jeker, Cimeo*
11:10-11:40	Allogeneic CAR T cells engineered with nonviral Sleeping Beauty transposon and CRISPR/Cas9 for cancer immunotherapy *Jaitip Tipanee, Ph.D., Vrije University of Brussel (VUB)*
11:40-11:55	*Refreshment break*
11:55-12:25	Therapeutic vascularization for regenerative medicine *Prof. Dr. Andrea Banfi, Basel University Hospital*
12:25-12:30	Promega solutions for cell and gene therapy *Richard Somberg, Promega*
12:30-13:00	Precision gene delivery by SHREAD VLPs for enhanced safety and efficacy *in vivo* *Sheena Smith, Ph.D., Vector BioPharma*
13:00-14:00	*Lunch break*
2nd session: Advancements in gene delivery *Session chair: Prof. Dr. Markus Ruegg (Biozentrum)*	
14:00-14:30	CRISPRing the genome: Lessons from evaluating on- and off-target effects *Prof. Dr. Toni Cathomen, Uniklinik Freiburg*
14:30-14:35	New organoid scaffold with fibrillar collagen, laminin, and hyaluronic acid *Alex Sim, AMSBIO*
14:35-15:05	Novel technologies for development of safer therapeutic genome editing medicines *Pinar Akcakaya, Ph.D., AstraZeneca*
15:05-15:20	*Refreshment break*
15:20-15:50	Targeted AAV for in vivo delivery using the "BloSsod" technology *Agostino Cirillo, Novartis*
15:50-15:55	From discovery to the clinic: Advancing CRISPR tools for cell and gene therapies *Tal Shamia, Ph.D., Synthego*
15:55-16:25	Immunological hurdles to AAV-mediated gene therapy, risk assessment and mitigation *Helene Haegel, Ph.D., Roche*
16:25-16:30	*Closing remarks*
16:30-18:00	*Networking*